Mirum Pharma CEO Peetz sells $2.48 million in shares

Mirum Pharmaceuticals (MIRM) reported robust Q2 2025 financial results, with revenues jumping 64% to $127.8 million and EPS exceeding expectations, prompting the company to raise its 2025 revenue guidance to $490M-$510M. This strong operational performance has driven positive analyst revisions and a "Strong Buy" consensus, with price targets up to $89. Concurrently, CEO Christopher Peetz executed a pre-planned sale of 40,000 shares for $2.48 million while also exercising options for an equivalent amount, as the stock trades near its 52-week high, signaling continued positive momentum despite the insider transaction.

Analysis

Mirum Pharmaceuticals (MIRM) is demonstrating significant operational momentum, underscored by strong second-quarter 2025 financial results. The company reported a 64% year-over-year revenue increase to $127.8 million, which surpassed consensus expectations by a notable 19.02%. The earnings per share of -$0.12 also represented a substantial beat against the forecasted -$0.33, signaling improved profitability. This robust performance has prompted management to raise its full-year 2025 revenue guidance to a range of $490 million to $510 million, implying a 48% year-over-year growth at the midpoint. The positive fundamental news has been met with a wave of analyst upgrades, with firms like H.C. Wainwright, JMP Securities, and Stifel increasing their price targets to as high as $89, reinforcing a "Strong Buy" consensus. Concurrently, the CEO's sale of 40,000 shares for $2.48 million should be viewed in context; the transaction was executed under a pre-disclosed Rule 10b5-1 plan and was accompanied by the exercise of options to acquire an equivalent number of shares at a low price of $2.936. This suggests a planned liquidity event rather than a loss of confidence, especially as the CEO maintains a substantial direct and indirect holding. However, the stock's recent 21% rally to near its 52-week high, coupled with an analysis suggesting it trades above its fair value, warrants consideration.

Key Decisions for Investors

• The combination of a significant revenue beat, raised full-year guidance, and multiple analyst price target upgrades provides a strong fundamental case for a continued bullish position on Mirum Pharmaceuticals.
• Given the stock has rallied over 20% in the past week to near its 52-week high, investors should be mindful of the elevated valuation and potential for short-term consolidation or profit-taking.
• The CEO's stock sale should be largely discounted as a negative signal, as it was part of a pre-arranged trading plan and offset by a simultaneous option exercise, indicating investors should focus on the company's compelling operational performance instead.